Merck (MRK) Dividends Paid - Common (2009 - 2026)
Merck (MRK) reported Dividends Paid - Common of $2.1 billion for Q1 2026, up 2.68% year-over-year from $2.1 billion in Q1 2025, and up 4.31% quarter-over-quarter from $2.0 billion in Q4 2025.
Merck (MRK) Dividends Paid - Common (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Dividends Paid - Common data on file, last reported at $2.1 billion in Q1 2026.
- Dividends Paid - Common for Q1 2026 came in at $2.1 billion, up 2.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.2 billion (up 3.66% YoY), and the FY2025 annual result was $8.2 billion, up 4.29% from the prior year.
- Dividends Paid - Common grew to $2.1 billion in Q1 2026 per MRK's latest filing, from $2.0 billion in the prior quarter.
- Over five years, Dividends Paid - Common peaked at $2.1 billion in Q1 2026 and troughed at $1.7 billion in Q1 2022.
- A 5-year average of $1.9 billion and a median of $2.0 billion in 2024 frame the typical range for Dividends Paid - Common.
- The sharpest annual moves came in 2022 and 2026: Dividends Paid - Common advanced 6.51% in 2022, then gained 2.68% in 2026.
- A 5-year view of Dividends Paid - Common shows it stood at $1.8 billion in 2022, then grew by 5.83% to $1.9 billion in 2023, then increased by 5.35% to $2.0 billion in 2024, then rose by 3.43% to $2.0 billion in 2025, then increased by 4.31% to $2.1 billion in 2026.
- Business Quant data shows MRK's Dividends Paid - Common at $2.1 billion in Q1 2026, $2.0 billion in Q4 2025, and $2.0 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dividends Paid - Common (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -866.88 Mn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 1.55 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 3.13 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 3.09 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 2.11 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 1.36 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 1.04 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 2.45 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 1.28 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.11 Bn |
| Mar 31, 2026 | 2.11 Bn |
| Dec 31, 2025 | 2.02 Bn |
| Dec 31, 2025 | 2.02 Bn |
| Sep 30, 2025 | 2.03 Bn |
| Sep 30, 2025 | 2.03 Bn |
| Jun 30, 2025 | 2.08 Bn |
| Jun 30, 2025 | 2.08 Bn |
| Mar 31, 2025 | 2.05 Bn |
| Mar 31, 2025 | 2.05 Bn |
| Dec 31, 2024 | 1.95 Bn |
| Dec 31, 2024 | 1.95 Bn |
| Sep 30, 2024 | 1.95 Bn |
| Sep 30, 2024 | 1.95 Bn |
| Jun 30, 2024 | 1.99 Bn |
| Jun 30, 2024 | 1.99 Bn |
| Mar 31, 2024 | 1.95 Bn |
| Mar 31, 2024 | 1.95 Bn |
| Dec 31, 2023 | 1.85 Bn |
| Dec 31, 2023 | 1.85 Bn |